We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Simpler and Reliable ALS Diagnosis Enabled With Blood Tests

By LabMedica International staff writers
Posted on 08 Feb 2022
Print article
Image: A blood test for neurofilaments can differentiate Amyotrophic lateral sclerosis (ALS) subgroups and ALS from common diagnostic mimics (Photo courtesy of The Association for Frontotemporal Degeneration)
Image: A blood test for neurofilaments can differentiate Amyotrophic lateral sclerosis (ALS) subgroups and ALS from common diagnostic mimics (Photo courtesy of The Association for Frontotemporal Degeneration)

Amyotrophic lateral sclerosis (ALS) is an adult onset fatal neurodegenerative syndrome characterized by the insidious onset of progressive motor symptoms and signs secondary to the loss of upper and lower motor neurons and their tracts.

Neurofilaments are neuron-specific cytoskeletal intermediate filament heteropolymers composed of neurofilament light chain (NFL), NF medium chain, and NF heavy chain (NFH) in combination with either α-internexin in the central nervous system or peripherin in the peripheral nervous system.

Clinical Scientists from the University of Gothenburg (Gothenburg, Sweden) and Umeå University (Umeå, Sweden) retrospectively quantified cerebrospinal fluid (CSF) NFL, CSF phosphorylated neurofilament heavy chain (pNFH) and plasma NFL in stored samples that were collected at the diagnostic work-up of 234 ALS patients, 44 ALS mimics, and nine controls. The team assessed the diagnostic performance, prognostication value and relationship to the site of onset and genotype.

CSF NFL concentrations were analyzed with a validated ELISA with intra- and interplate variations of < 8% and < 13%, respectively. CSF NFL analyses were performed in duplicates. Two control samples were not analyzed for CSF NFL due to the limited CSF volume. CSF pNFH concentrations were measured with an in-house-developed ELISA with minor modifications with intra- and interplate variations of < 3.9% and < 9.4%, respectively. Regarding CSF pNFH analyses, 226 samples were evaluated in singlicates due to the limited CSF volume. Plasma NFL concentrations were measured using a single-molecule array (SIMOA) assay on an HD-1 Analyzer (Quanterix, Billerica, MA, USA) with intra- and interplate variations of < 10% and < 12%, respectively.

The investigators reported that CSF NFL, CSF pNFH and plasma NFL levels were significantly increased in ALS patients compared to patients with neuropathies and myelopathies, patients with myopathies and controls. Furthermore, CSF pNFH and plasma NFL levels were significantly higher in ALS patients than in patients with other MNDs. Bulbar onset ALS patients had significantly higher plasma NFL levels than spinal onset ALS patients. ALS patients with C9orf72HRE mutations had significantly higher plasma NFL levels than patients with SOD1 mutations. Survival was negatively correlated with all three biomarkers.

Arvin Behzadi, a doctoral student and first author of the study, said, “Finding suspected cases of ALS through a blood test opens up completely new opportunities for screening and measuring neurofilaments in blood collected longitudinally enables easier quantification of treatment effects in clinical drug trials compared to longitudinal collection of CSF. Finding ALS early in the disease course may facilitate earlier administration of pharmaceutical treatment, before the muscles have atrophied.”

The authors concluded that all three biomarkers are of clinical value in affirming an ALS diagnosis and excluding potential ALS mimics. CSF pNFH showed the highest AUC in terms of differentiating ALS from ALS mimics. Plasma NFL analysis has the advantage that it does not require a lumbar puncture, has only a minimal difference in diagnostic performance compared to CSF NFL levels and shows the highest AUC in terms of prognosticating ALS short and long survival. The study was originally on November 11, 2021 in the journal Scientific Reports.

Related Links:
University of Gothenburg 
Umeå University 
Quanterix 

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article

Channels

Molecular Diagnostics

view channel
Image: The HelioLiver Dx test has met the coprimary and secondary study endpoints in the CLiMB trial (Photo courtesy of Helio Genomics)

Blood-Based Test Outperforms Ultrasound in Early Liver Cancer Detection

Patients with liver cirrhosis and chronic hepatitis B are at a higher risk for developing hepatocellular carcinoma (HCC), the most prevalent type of liver cancer. The American Association for the Study... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The POC PCR test shortens time for STI test results (Photo courtesy of Visby Medical)

POC STI Test Shortens Time from ED Arrival to Test Results

In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2.5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.